How effective is baricitinib as an antirheumatic drug?

Baricitinib has significant efficacy as an anti-rheumatic drug. It mainly inhibits the proliferation and activation of inflammatory cells and effectively relieves joint pain, swelling and other symptoms caused by rheumatoid arthritis.

Baricitinib has shown significant efficacy in clinical trials. For example, in the RA-BALANCE study, patients in the baricitinib treatment group met the primary endpoint and showed good therapeutic effects compared with the placebo group. Another clinical trial called RA-BEACON also showed that patients treated with baricitinib had a significant improvement in ACR20 scores, which means that the patient's symptoms were improved by at least 20%. Specifically, among patients taking baricitinib2 mg after the 12th week of treatment, 49%achieved ACR20remission, significantly better than 27% in the placebo group.

A distinctive feature of baricitinib in the treatment of rheumatoid arthritis is its ability to rapidly relieve symptoms. In clinical trials, some patients experienced improvements in ACR20 in the first week of treatment, demonstrating baricitinib's ability to quickly relieve patients' pain.

In addition to the relief of joint pain and swelling, baricitinib can significantly improve patients' physical function, including physical function, pain, fatigue and quality of life. This means that after using baricitinib, patients not only have their symptoms relieved, but their overall quality of life has also been improved.

The long-term study showed that baricitinib maintained a similar safety profile to that in the early analysis over several years of treatment, and no new safety signals were discovered. This indicates that baricitinib has durable efficacy and good safety profile in the treatment of rheumatoid arthritis.